Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders

US11485786B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Ilhan Celik · Zwingenberg, DE
• Eike Staub · Darmstadt, DE
• Miriam Urban · Leidersbach, DE
• Sabine Raab · Rosbach, DE
• Eileen Samy · Arlington, US
• Andrew Bender · Reading, US
• Georgianna Higginbotham · Tewksbury, US
• Yin Wu · Andover, US
• Daigen Xu · Ottawa, CA

Key dates

• Filing date: Aug 15, 2019
• Grant date: Nov 1, 2022
• Expiry date: Aug 15, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting αv-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.